Nykredit A S Takes Position in West Pharmaceutical Services, Inc. $WST

Nykredit A S bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 26,405 shares of the medical instruments supplier’s stock, valued at approximately $9,479,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Sound Financial Strategies Group LLC acquired a new position in shares of West Pharmaceutical Services during the second quarter worth $388,000. Proficio Capital Partners LLC bought a new position in West Pharmaceutical Services during the 2nd quarter worth $381,000. Benjamin Edwards Inc. lifted its holdings in West Pharmaceutical Services by 47.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 5,322 shares of the medical instruments supplier’s stock worth $1,911,000 after buying an additional 1,720 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at about $11,129,000. Finally, Greenleaf Trust increased its stake in shares of West Pharmaceutical Services by 4.1% in the second quarter. Greenleaf Trust now owns 843 shares of the medical instruments supplier’s stock valued at $303,000 after buying an additional 33 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Down 0.8%

Shares of West Pharmaceutical Services stock opened at $339.90 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The stock has a 50 day moving average price of $350.55 and a two-hundred day moving average price of $306.92. The stock has a market capitalization of $23.92 billion, a PE ratio of 43.52, a price-to-earnings-growth ratio of 2.38 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period in the prior year, the firm earned $1.84 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.27%.

Analyst Ratings Changes

Several analysts recently commented on the company. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Wolfe Research began coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. TD Cowen reiterated a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Evercore reissued an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Finally, Stephens reissued an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.